Hyponatremia in Oncology Patients.
Journal
Frontiers of hormone research
ISSN: 1662-3762
Titre abrégé: Front Horm Res
Pays: Switzerland
ID NLM: 0320246
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
20
6
2020
Statut:
ppublish
Résumé
Hyponatremia is frequent in cancer patients and potentially deleterious. Cancer patients have specific requirements due to the nature and treatment of their disease, which can directly impact the occurrence and severity of hyponatremia, and limit treatment choices. Although essential for successful hyponatremia management, appropriate diagnostic testing is not routinely performed in the current practice. Despite clear evidence that hyponatremia is associated with poor outcome in oncology patients, most patients are still hyponatremic while under observation. Guidance on specific treatment of cancer patients with hyponatremia is needed to optimize patient care in the face of these challenges.
Identifiants
pubmed: 32097904
pii: 000493245
doi: 10.1159/000493245
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-166Informations de copyright
© 2019 S. Karger AG, Basel.